CN1313605C - Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method - Google Patents
Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method Download PDFInfo
- Publication number
- CN1313605C CN1313605C CNB2005100409739A CN200510040973A CN1313605C CN 1313605 C CN1313605 C CN 1313605C CN B2005100409739 A CNB2005100409739 A CN B2005100409739A CN 200510040973 A CN200510040973 A CN 200510040973A CN 1313605 C CN1313605 C CN 1313605C
- Authority
- CN
- China
- Prior art keywords
- strain
- gene
- cgtctc
- subtype
- duck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 82
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 41
- 238000010276 construction Methods 0.000 title claims abstract description 5
- 241000287828 Gallus gallus Species 0.000 claims abstract description 69
- 101150039660 HA gene Proteins 0.000 claims abstract description 30
- 241000272525 Anas platyrhynchos Species 0.000 claims abstract description 25
- 101150080862 NA gene Proteins 0.000 claims abstract description 22
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 20
- 241001473385 H5N1 subtype Species 0.000 claims abstract description 16
- 239000013612 plasmid Substances 0.000 claims description 39
- 206010016256 fatigue Diseases 0.000 claims description 25
- 230000003321 amplification Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000002299 complementary DNA Substances 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 239000013613 expression plasmid Substances 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 210000002257 embryonic structure Anatomy 0.000 claims description 7
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims description 6
- 238000001502 gel electrophoresis Methods 0.000 claims description 5
- 241001473386 H9N2 subtype Species 0.000 claims description 4
- 241001500351 Influenzavirus A Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 239000012096 transfection reagent Substances 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 101150028074 2 gene Proteins 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 241000252872 H6N1 subtype Species 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 abstract description 12
- 238000005516 engineering process Methods 0.000 abstract description 9
- 206010022000 influenza Diseases 0.000 abstract description 7
- 230000005180 public health Effects 0.000 abstract description 5
- 230000002068 genetic effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 abstract 2
- 235000013330 chicken meat Nutrition 0.000 description 59
- 241000700605 Viruses Species 0.000 description 33
- 101710154606 Hemagglutinin Proteins 0.000 description 32
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 32
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 32
- 101710176177 Protein A56 Proteins 0.000 description 32
- 239000000185 hemagglutinin Substances 0.000 description 31
- 230000036039 immunity Effects 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 16
- 238000005336 cracking Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 13
- 239000002574 poison Substances 0.000 description 13
- 230000004224 protection Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 230000009849 deactivation Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 210000003837 chick embryo Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960003971 influenza vaccine Drugs 0.000 description 7
- 208000002979 Influenza in Birds Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000007918 pathogenicity Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 230000003067 hemagglutinative effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000272814 Anser sp. Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101150076514 NS gene Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003555 cloaca Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010092265 CCWGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 101100008050 Caenorhabditis elegans cut-6 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 108010033155 GGGCCC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
一种禽流感病毒基因重配株D3/F-R2/6及其构建方法，涉及应用反向遗传技术。将MPAIV鸡胚高度适应株A/Chicken/Shanghai/F/98(H9N2)的6个内部基因PB2、PB1、PA、NP、M、NS和HPAIV流行株A/Duck/Huadong/D3/00(H5N1)的NA基因和致弱的HA基因进行重配，构建成禽流感病毒基因重配株D3/F-R2/6。可用于制造禽流感疫苗，以避免采用人流感病毒的内部基因和AIV的表面基因重配成新的A型流感病毒制备禽流感疫苗时，对公共卫生构成威胁。An avian influenza virus gene reassortment strain D3/F-R2/6 and its construction method involve the application of reverse genetic technology. Six internal genes PB2, PB1, PA, NP, M, NS of MPAIV chicken embryo highly adapted strain A/Chicken/Shanghai/F/98 (H9N2) and HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1 ) of the NA gene and the weakened HA gene were reassorted to construct the avian influenza virus gene reassortment strain D3/F-R2/6. It can be used to manufacture bird flu vaccines to avoid threats to public health when the internal genes of human influenza viruses and the surface genes of AIV are reassorted into new type A influenza viruses to prepare bird flu vaccines.
Description
Technical field
The present invention relates to use the reverse genetic technology.Particularly (be called for short: H5N1 hypotype AIV) two outside genes and a strain H9N2 subtype avian influenza virus (are called for short: 6 internal gene H9N2 hypotype AIV) with a strain H5N1 subtype avian influenza virus, be built into 8 genes all from the gene resortment virus strain of AIV, be used to make vaccine.
Background technology
The reverse genetic manipulation technology of RNA viruses is meant external by making up the infective molecule cloning of RNA viruses, be about to the virus genome RNA reverse transcription and become cDNA, on the dna molecular level, it is carried out various external manual operations, assemble a technology of new RNA viruses by viral genome cDNA and various accessory protein.Because the RNA viruses that final " rescue " goes out derives from the cDNA clone, therefore, can be by the artificial dna circle joint that adds in the pilot process, on dna level, the rna virus cdna group is carried out various external manual operations, as carry out transformations such as transgenation, gene knockout (disappearance), gene insertion, gene substitution and gene complementation.This technology not only can be used to study the gene replication of RNA viruses and expression regulation mechanism, antiviral strategy, gene therapy, and can be used for making up new vaccine virus.
The genome of influenza virus is made of 8 single-stranded RNAs, and the different segment of virus has different effects aspect pathogenic in that decision is viral, and what wherein play a major role is HA albumen.The acceptor that it can the recognition of host cell and combine with it at first, the specificity of influenza virus HA protein receptor depends on host's kind.Next be HA by protease cracking be HA1 and HA2 characteristic [the Gan Menghou chief editor. bird flu. second edition, Beijing: agriculture press, 2002.], HA is subjected near glycosylated influence aminoacid sequence at cracking site place and the site by the characteristic of protease cracking.The low pathogenicity strain has only a basic amino acids arginine (R) at the cracking site place, and the highly pathogenicity strain has a plurality of basic aminoacidss [Bosch FX, GartenW, Klenk HD, et al.Proteolytic cleavage of influenza virus hemagglutininprimary structure of the connecting site of avian influenzavirus.Virology, 1981,113 (2): 725-735].Most highly pathogenic influenza viruses are arginine (R) at the C of HA1 end, the N end of HA2 is glycine (G), also there is the C end of few part HA1 to be Methionin (K) [Gunther I, Glatthaar B, Doller G, et al.A H1 hemagglutinin of a humaninfluenza A virus with a carbohydrate-modulated receptor binding site and anunusual cleavage site.Virus Res, 1993,27 (2): 147-160.], the proline(Pro) (P) of H5 hypotype HA1C end upstream is conservative in different strains with L-glutamic acid (Q).All have four conserved amino acid R-E-T-R from the isolating low pathogenicity H5 of nature strain major part between Q and G, promptly-and P-Q-R-E-T-R ↓ G (" ↓ " is cracking site); And the H5 strain of highly pathogenicity is near the HA cracking site during sugar based side chain, its sequence is-P-Q-B-X-B-R ↓ G (B is any basic aminoacids), if when near the HA cracking site glycosylation side chain being arranged, then must insert any two amino acid, sequence is-P-Q-X-X-B-X-B-R ↓ G or-P-Q-B (X)-X (B)-B-X-B-R ↓ G, otherwise the not high [SenneDA of virulence, Panigrahy B, Kawaoka Y, et al.Survey of the hemagglutinin (HA) cleavagesites sequence of H5 and H7 avian influenza viruses:amino acid sequence at theHA cleavage site as a marker of pathogenicity potential.Avian Dis, 1996,40 (2): 425-37.].
Because influenza virus has a lot of hypotypes, and same hypotype also has different variants, and this makes selects to produce influenza vaccines and with suitable strain very big difficulty is arranged.In addition, some strain isolated can not be bred and enough high titre, need take efforts and concentrate vaccine [the Palese P that enough protections are arranged with production, Garc í a-Sastre.Influenza A Vaccines:present and future.Clinical Investigation, 2002,110:9-13.]; Because the easy variability of influenza antigen all will be reappraised the matching of vaccine every year, this process is time-consuming requires great effort again simultaneously.But the reverse genetic manipulation technology has been quickened this process greatly, only the HA of epidemic strain and the NA gene plasmid combination cotransfection cell with the internal gene that builds in advance just can need be obtained needed vaccine strain.As [Subbarao K such as Subbarao K, Chen H, Swayne D, et al.Evalution of a Genetically Modified Reassortant H5N1Influenza A Virus Vaccine Cadidate Generated by Plasmid-Based ReverseGenetics.Virology, 2003,305:192-200.] made up H5N1/PR8 reprovision virus, this viral HA is from the HA of A/Hong Kong/97 (H5N1), remove 5 basic aminoacidss at HA cracking position through genetic modification, adopt 12 pUC pUCs to produce H5N1/PR8 virus, make it to become low virulent strain, the virus that is produced all causes weak to mouse and chicken.Chen H etc. adopt with quadrat method and make up generation H9N2/PR8 virus, wherein H9N2 is fowl source A/CK/HK/G9 (H9N2) strain [Chen H, Subbarao K, SwayneD.et al.Generation and Evaluation of a high-growth Reassortant H9N2 InfluenzaA virus as a Vaccine Candidate.Vaccine, 2003,21,1983-1988.].Hoffmann E etc. utilizes 8 plasmid rescue systems to produce H1N1/PR8, H9N2/PR8, H3N2/PR8, H6N1/PR8 strain [Hoffmann E, Krauss S, Perez D, et al.Eight-plasmid system for rapidgeneration of influenza virus vaccines.Vaccine, 2002, Aug, 19; 20 (25-26): 3165.].The HA of H5N3/PR8 low virulent strain on the chicken embryo of structures such as Liu M tires up to 1: 2
11Inactivated vaccine can be protected the attack of chicken to strong poison; compare with commercialized vaccine; can stop toxin expelling [Liu M more significantly; Wood JM, Ellis T.Preparation of a standardized, efficacious agricultural H5N3vaccine by reverse genetics.Virology; 2003,314:580-90.].Lu Jianhong etc. utilize 8 plasmid rescue systems to produce the causing weak H5 hypotype reprovision influenza virus of H5N1/WSN and H5N2/WSN, and are not high but duplicating in the chicken embryo dripped poison, the antibody that direct inoculation SPF chicken produces also very low (2
1-3) [Lu Jianhong, Long Jinxue, Shao Weixing, etc. cause weak H5 hypotype reprovision influenza virus with the generation of reverse genetic manipulation technology. microorganism journal, 2005,45 (1): 53-57].The H5N1/PR8 virus avian influenza vaccine of domestic existing registration at present.But the reprovision virus that above research produces, its internal gene is all from people source influenza virus A/PR/8/34 (H1N1) or A/WSN/33 (H1N1) strain.The A type influenza virus of experiment indoors artificial with the surperficial gene resortment Cheng Xin of human influenza virus's internal gene and AIV, because influenza virus is segmented minus-stranded rna virus, gene resortment forms novel influenza virus and causes that the pandemic possibility of human influenza is very big, therefore its public health that may exist threatens, caused some experts' worry, and the internal gene of weak pathogenic AIV is carried out reprovision with the surperficial gene that causes weak highly pathogenic AIV, produce the full fowl of 8 genes source virus, this danger is much smaller.
Summary of the invention
First purpose of the present invention is to invent a kind of 8 genes all from the weak H5N1 hypotype AIV gene resortment strain D3/F-R2/6 that causes of AIV, be used to produce avian influenza vaccine, in the time of can avoiding adopting the production of Influenza virus avian influenza vaccine of surperficial gene resortment Cheng Xin of human influenza virus's internal gene and AIV, the threat that may cause public health.
The preserving number of avian influenza virus gene resortment strain D3/F-R2/6 of the present invention is CGMCC NO:1386, genome length is 13.5Kb, be made of two the outside genes of H5N1 hypotype AIV and 6 internal gene PB2, PB1, PA, NP, M, the NS of MPAIV chicken embryo height adapted strain A/Chicken/Shanghai/F/98 (H9N2), two outside genes of described H5N1 hypotype AIV are respectively the NA genes of HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1) and cause weak HA gene.
The weak HA gene DNA sequence that causes of HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1) is:
atggagaaaa tagtgcttct tcttgcaata gtcagtcttg ttaaaagtga tcagatttgc 60
attggttacc atgcaaacaa ctcgacagag caggttgaca caataatgga aaagaacgtt 120
actgttacgc atgcccaaga catactggaa aaggcacaca acgggaaact ctgcgatcta 180
gatggagtga agcctctaat tttgggagat tgtagtgtagc tggatggctc ctcggaaac 240
cctatgtgtg acgaattcat caatgtgccg gaatggtctt acatagtggg gaaggccagt 300
ccagccaatg acctctgtta cccaggggat ttcaacgact atgaagaact gaaacaccta 360
ttgagcagaa taaaccactt tgagaaaatt cagatcatcc ccaaaagttc ttggtccaat 420
catgaagcct catcaggggt gagcgcggca tgtccatacc atgggaagcc ctcctttttc 480
agaaatgtgg tatggcttat caaaaagaac agtgcatacc caacaataaa gaggagctac 540
aataacacca accaagaaga tcttttggta ctgtggggga ttcaccatcc taatgatgca 600
gcagagcaga caaagctcta tcaaaaccca accacctata tctccgttgg aacatcaaca 660
ttaaaccaga gattggtccc aaaaatagct actagatcca gagtaaacgg gcaaagtgga 720
agaatggagt tcttctggac aattttaaag ccgaatgatg ccataaattt cgagagtaat 780
gggaatttca ttgctccaga atacgcatac aaaattgtca agaaagggga ctcagcaatt 840
atgaaaagtg aattggaata tggtaactgc aacaccaagt gtcaaactcc aatgggggcg 900
ataaactcta gtatgccatt ccacaacata caccctctca ccatcgggga atgccccaaa 960
tatgtgaaat caaacagatt agtccttgcg actagactca gaaatacccc tcaaagagag 1020
agaaggagaa aaaagagagg actatttgga gctatagcag gttttataga gggaggatgg 1080
cagggaatgg tagatggttg gtatgggtac caccatagca atgagcaggg gagtggatac 1140
gctgcagaca aagaatccac tcaaaaggca atagatggag tcaccaataa ggtcaactcg 1200
atcattgaca aaatgaacac tcagtttgag gccgttggaa gggaatttaa taacttagaa 1260
aggaggatag aaaatttaaa caagaagatg gaagacggat tcctagatgt ctggacttat 1320
aatgctgaac ttctggttct catggaaaat gagagaactc tagactttca tgattcaaat 1380
gtcaagaacc tttacaacaa ggtccgacta cagcttaggg ataatgcaaa ggagctgggt 1440
aatggttgtt tcgagttcta tcacaaatgt gataatgaat gtatggaaag tgtaaaaaac 1500
gggacgtatg actacccgca gtattcagaa gaagcaagac taaacagaga ggaaataaat 1560
ggagtaaaat tggaatcaat gggaacttac caaatactgt caatttattc aacagtggcg 1620
agttccctag cactggcaat catggtagct ggtctatctt tatggatgtg ctccaatgga 1680
tcgttacaat gcagaatttg catttaa
The NA gene DNA sequence of HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1) is:
agcaaaagca ggagttcaaa atgaatccaa atcaaaagat aataaccacc ggatcaatct 60
gtatggtaatt ggaatggtta gcttgatgtt gcaaattgg gaacataatc tcaatatggg 120
ttagtcattc aattcagaca gggactcaac accgagctga accatgcaat cgaagcatta 180
ttaattatga aaacaacacc tgggtaaatc agacatatgt caaaatcagc aacaccaatt 240
ttcttactga gaaagctgtg gcttcagtaa gattagtggg caattcatct ctttgcccca 300
tgtttgttat aagagagccg ttcatctcat gctcccactt ggaatgccga accttctttt 360
tgactcaggg agccttgctg aatgataagc actccaatgg gaccgtcaaa gacagaagcc 420
cttacagaac attgatgagc tgtcctgtgg gtgaggcccc ctccccatat aactcgaggt 480
ttgagtctgt tgcttggtcg gcaagtgctt gtcatgatgg cactagttgg ttgacaattg 540
gaatttctgg cccagacaat ggggctgtgg ctgtattgaa atacaatggc ataataacag 600
acactatcaa gagttggagg aacaacatac tgagagctca agagtctgaa tgtgcatgtg 660
taaatggctc ttgctttact gtaatgactg acggaccaag taatgggcag gcttcatata 720
agatcttcaa aatagaaaaa gggaaagtag ttaaatcagt cgaattgaat gcccctaatt 780
atcactatga ggagtgctcc tgttatcctg atgctggcga aatcacatgt gtgtgcaggg 840
ataattggca tggctcaaat cggccatggg tatctttcaa tcaaaatttg gagtaccaaa 900
taggatatat atgcagtgga gttttcggag acaatccacg ccccaatgat ggaacaggca 960
gttgtggtcc ggtgtcccct aacggggcat atggagtaaa agggttttca tttaaatacg 1020
gcaatggtgt ttggatcggg agaaccaaaa gcactaattc caggagcggc tttgaaatga 1080
tttgggatcc aaatgggtgg actggaacgg acagtaattt ttcggtgaag caagatatcg 1140
tagctataac tgattggtca ggatatagcg ggagttttgt ccagcatcca gaactgacag 1200
gattagattg cataagacct tgtttctggg ttgagctaat cagagggcgg cccaaagaga 1260
gcacaatttg gactagtggg agcagcatat ctttttgtgg tgtaaatagtgacactgtgg 1320
gttggtcttg gccagacggt gctgagttgc cattcaccat tgacaagtag tttgttcaaa 1380
aaactccttg tttctact。
6 internal gene PB2, the PB1 of above-mentioned MPAIV chicken embryo height adapted strain A/Chicken/Shanghai/F/98 (H9N2), PA, NP, M, NS sequence are seen GenBank, and accession number is AY253750, AY253751, AY253752, AY253753, AY253755, AY253756.Avian influenza virus gene resortment strain D3/F-R2/6 on June 6th, 2005 in the survival preservation of China Committee for Culture Collection of Microorganisms common micro-organisms center, preserving number is CGMCC NO:1386.
The present invention can be used for making avian influenza vaccine, when preparing avian influenza vaccine with the A type influenza virus of the surperficial gene resortment Cheng Xin of the internal gene of avoiding adopting the human influenza virus and AIV, public health is constituted a threat to.
Second purpose of the present invention is to invent the construction process of a kind of avian influenza virus gene resortment strain D3/F-R2/6:
With the NA gene of 6 internal gene PB2, PB1, PA, NP, M, NS and the HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1) of MPAIV chicken embryo height adapted strain A/Chicken/Shanghai/F/98 (H9N2) with cause weak HA gene and carry out reprovision, be built into avian influenza virus gene resortment strain D3/F-R2/6.
The present invention is 6 internal gene of two outside genes and the strain H9N2 hypotype AIV of a strain H5N1 hypotype AIV, is built into 8 genes all from the gene resortment virus strain of AIV.Because the influenza virus rescue system based on plasmid that adopts now is to use primates zooblast as transfectional cell, can the weak pathogenic AIV in therefore full fowl source produce in primates zooblast, also unknown.Also rarely seen at home and abroad 8 genes are all reported from the rescue of AIV especially H9N2 hypotype AIV.And the F strain is weak pathogenic H9N2 hypotype AIV, and its levels of replication in primates zooblast is restricted, and has both made the content that increases pancreatin also be not enough to save out virus.The host that the most suitable F strain AIV duplicates is a development of chick embryo, and Fan Zhi virus titer can reach 2 therein
11We have improved transfection method for this reason: be about to 24h behind the plasmid transfection cell, just the cell inoculation 10 age in days SPF chicken embryos of transfection plasmid, hatch behind the 48h on SPF chicken embryo amplification once again.The result saves out avian influenza virus gene resortment strain D3/F-R2/6 on the isolating F strain basis, China's Mainland of having saved out the full fowl of 8 genes source.
The present invention utilizes the reverse genetic technology, with 1998 China's Mainland isolated M PAIV chicken embryo height adapted strain A/Chicken/Shangha/F/98 (H9N2) 6 internal gene and HPAIV epidemic strain A/Duck/Huadong/D3/00 (H5N1) cause weak HA gene and NA gene and carry out reprovision, that successfully saves out 6+2 combination causes 8 weak genes all from the gene resortment AIV of AIV, and to its virulence, after pathogenic and immune efficacy is identified, the present invention is workable for proof, stable performance, can avoid adopting the A type influenza virus of the surperficial gene resortment Cheng Xin of human influenza virus's internal gene and AIV, when making avian influenza vaccine, public health is constituted a threat to.
The present invention includes following concrete steps:
1) 6 internal gene PB2, PB1, PA, NP, M, the NS of MPAIV A/Chicken/Shanghai/F/98 (H9N2) strain of amplification chicken embryo height adaptation.
The amplimer sequence is as follows:
Bm-PB2-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGTC-3’；
Bm-PB2-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTCGTTT-3’；
Bm-PB1-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGCA-3’；
Bm-PB1-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGCATTT-3’；
Bm-PA-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGTACTGAT-3’；
Bm-PA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTACTTTT-3’；
Bm-NP-1 5’-TATT
CGTCTCAGGGAGCA AAAGCAGGGTAGATAATC-3’；
Bm-NP-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTATTTTTC-3’；
Bm-M-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGTAG-3’；
Bm-M-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTAGTTTTT-3’；
Bm-NS-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGGTG-3’；
Bm-NS-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’；
2) increase respectively the HA gene and the NA gene of HPAIV A/Duck/Huadong/D3/00 (H5N1) strain, the primer sequence of amplification HA and NA gene is as follows:
Bm-HA-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGGG-3’；
Bm-HA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’；
Bm-NA-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGAGT-3’；
Bm-NA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGAGTTTTTT-3’；
3) the HA gene of modification H5N1 hypotype HPAIV A/Duck/Huadong/D3/00 (H5N1) strain: the cracking site PQIETR ↓ GL that the cracking site PQRERRRKKR ↓ GL of HA gene is sported non-virulent influenza virus A/Teal/Hong Kong/W312/97 (H6N1) strain HA;
4) the HA gene cDNA of H5N1 hypotype HPAIV A/Duck/Huadon/DD3/00 (H5N1) strain after will modifying is cloned into pHW2000 through 3 molecule connection methods, makes up to cause weak A/Duck/Huadong/D3/00 (H5N1) strain HA gene transcription/expression vector plasmid pHW504-HA;
5) make up transcribing/expression plasmid of 6 internal gene: transcribe at 8 plasmids/expression vector pHW2000 in, insert 6 of 6 internal gene of F strain (PB2, PB1, PA, NP, M, NS) cDNA formation respectively and transcribe/expression plasmid, be i.e. pHW201-PB2, pHW202-PB1, pHW203-PA, pHW205-NP, pHW207-M, pHW208-NS;
6) make up the NA gene transcription/expression plasmid of HPAIV A/Duck/Huadong/D3/00 (H5N1) strain: the NA gene of transcribing/inserting among the expression vector pHW2000 HPAIVA/Duck/Huadong/D3/00 (H5N1) strain at 8 plasmids forms pHW506-NA;
7) 6+2 gene resortment: will be from 6 plasmid pHW201-PB2, pHW202-PB1 of F strain, pHW203-PA, pHW205-NP, pHW207-M, pHW208-NS with from 2 plasmid pHW504-HA, pHW506-NA of A/Duck/Huadong/D3/00 (H5N1) strain, mixed by 1: 1, blended plasmid and transfection reagent are added in the COS-1 cell, put and contain 5%CO
2, in 37 ℃ of incubators, cultivate switching kind of 10 age in days SPF chicken embryos behind the 24h, promptly obtain avian influenza virus gene resortment strain D3/F-R2/6.
Above-mentioned steps 4) in by two pairs of primers increase respectively HA1 (1.05kb) and two fragments of HA2 (0.65kb), HA1 and HA2 that gel electrophoresis is reclaimed cut, reclaim through the BsmBI enzyme, with equally carry out 3 molecule ligations, 16 ℃ of effect 12h through transcribing of cutting of BsmBI enzyme/expression vector pHW2000;
Two pairs of primers are respectively:
Bm-HA-1 5’-TATTCGTCTCAGGGAGCAAAAGCAGG-3’；
Bm-HA-2 5’-ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’；
P-MG4-1 5’-ACATCGTCTCACTAGAGGATTATTTGGAGCTAT-3’；
P-MG4-2 5’-AGATCGTCTCTTCAATTTGAGGGCTTTTTCTGAGTCC-3’。
Description of drawings
Fig. 1 is for modifying D3 strain HA gene cracking site synoptic diagram.
Fig. 2 is cloned into the pHW2000 connection diagram for the HA gene cDNA of D3 strain after modifying through 3 molecule connection methods.
Specific embodiment
MPAIV and HPAIV strain that the present invention selects, these two strains must have good immunity, higher replication is arranged in the chicken embryo.The present invention has selected MPAIV A/Chicken/Shahghai//98 (H9N2) strain as the H9N2 subgroup vaccine, be abbreviated as the F strain, this strain is by the livestock and poultry loimology emphasis open laboratory's separation and purification of the Ministry of Agriculture of Yangzhou University, be accredited as the H9N2 hypotype through national influenza center, the complete genome sequence login is at GenBank, accession number is red for Lu AY253750-AY253756[builds, Liu Xiu Buddhist, Shao Weixing, genetic analysis Deng .H9N2 hypotype AIV genome full length sequence mensuration and each gene. the microorganism journal, 2003,43 (4): 434-41.].Select HPAIV A/Duck/Huadong/D3/00 (H5N1) strain, abbreviate the D3 strain as, this strain is accredited as the H5N1 hypotype by the livestock and poultry loimology emphasis open laboratory's separation and purification of the Ministry of Agriculture of Yangzhou University through national influenza center.
The preparation of 8 used plasmid virus rescue systems among the present invention: the 8 plasmid virus rescue pHW2000 of system are so kind as to give [HoffmannE by Robert doctor Webster of U.S. St.Jude child study hospital, Neumann G, Kawaoka Y, et al.A DNA transfection system for generation ofinfluenza A virus from eight plasmids.Proc.Natl.Acad.Sci.USA, 2000,97:6108～13.].
Step 1: the extraction of F strain and D3 strain RNA
F strain and D3 strain seed culture of viruses are inoculated in SPF chicken embryo, collect allantoic fluid 300ml, and the centrifugal 15min of 6000rpm (30# rotor) gets supernatant; 4 ℃ of centrifugal 1.5h of 18000rpm are with 40ml STE (10mMpH8.0 Tris-HCl, 100mM NaCl, 5mM pH8.0 EDTA) suspension precipitation.Rebasing with 10% sucrose, carefully add suspension, 4 ℃ of centrifugal 1.5h foreigh protein removings of 18000rpm are abandoned supernatant, and precipitation suspends with 30mL STE, and 4 ℃ of centrifugal 1h of 18000rpm remove sucrose, and precipitation suspends with 7mL STE, packing dactylethrae, every pipe 450 μ L.
The RNA extraction agent box of using marine life engineering Services Co., Ltd extracts RNA.Get the above-mentioned viral liquid preparation of 300 μ L, add the abundant mixing of 400 μ L Trizol, add 100 μ L chloroform/primary isoamyl alcohol (24: 1) again, jolt 30 seconds after, 12, centrifugal 5 minutes of 000rpm; Move supernatant to aseptic 1.5mL RNase-free centrifuge tube, add 150 μ L dehydrated alcohols, mixing; Place the MNIQ-10 post, room temperature was placed 2 minutes, and 8, centrifugal 1 minute of 000rpm; Discard waste liquid, in pillar, add 450 μ L Solution RPE, 10,000rpm, centrifugal 30 seconds; The step once before repeating; Discard waste liquid, 10,000rpm, centrifugal 15 seconds; Move pillar and go in aseptic, the RNase-free centrifuge tube, central authorities add 50 μ L DEPC-H at pillar
2O placed 2 minutes for 55-80 ℃, and 10,000rpm, centrifugal 1 minute, the solution in the collection tube was the RNA sample.
Step 2: 6 internal gene of F strain and the HA of D3 strain and amplification, clone and the sequencing of NA gene
The design primer is with 6 internal gene of reverse transcription-polymerase chain reaction (RT-PCR) method amplification F strain, the HA of D3 strain and NA gene, respectively with each PCR product cloning order-checking, and with each gene openly sequence compare.
The primer sequence of 6 internal gene of amplification F strain is as follows:
Bm-PB1-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGCA-3’；
Bm-PB1-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGCATTTT3’；
Bm-PA-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGTACTGAT-3’；
Bm-PA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTACTTTTT3’；
Bm-NP-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGGTAGATAATC-3’；
Bm-NP-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTATTTTTC-3’；
Bm-PB2-1 5’-TATT
CGTCTCAGGGAGCGAAAGCAGGTC-3’；
Bm-PB2-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTCGTTT-3’；
Bm-M-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGTAG-3’；
Bm-M-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGTAGTTTT3’；
Bm-NS-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGGTG-3’；
Bm-NS-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’。
12uni 5’-AGCAAAAGCAGG-3’
The HA of amplification D3 strain and the primer sequence of NA gene are as follows:
Bm-HA-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGGG-3’；
Bm-NA-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGGAGT-3’；
Bm-NA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGAGTTTTTT-3’；
Bm-HA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’。
For convenient above 8 gene fragment clones to transcribe/expression vector pHW2000 (transcribe/expression vector on the BsmBI restriction enzyme site is arranged) in, when designing the primer of pcr amplification gene fragment, add clone's restriction enzyme site BsmBI site at 5 of upstream and downstream primer ' end, be abbreviated as Bm, band underscore place is the recognition site of corresponding enzyme.In addition, design the universal primer (12uni) of making RT, be used for reverse transcription with the 12nt that all segment cDNA 5 ' end all has.All primers are synthetic by precious biological (Dalian) company limited.
Reverse transcription F strain and the full genome of D3 strain (25 μ l reaction system):
Get the F strain or the D3 pnca gene group RNA 15 μ l of above extraction respectively, add 70 ℃ of sex change 5min of 1 μ l 50pmol/L12nt primer, put 0 ℃ immediately, add following reagent then successively:
5×RT buffer 5μL
RNasin(40U/μL) 1μL
10mM dNTPs 2μL
(10U/μL)
42 ℃ the effect 1h, can use immediately or put-20 ℃ standby.
Pcr amplification HA and NA full length fragment (50 μ L reaction system):
Get respectively in above-mentioned RT product (cDNA) 10 μ L to the 0.5mL PCR reaction tubess, use primer Bm-PB2-1 and Bm-PB-2 when wherein increasing the PB2 fragment; Use primer Bm-PB1-1 and Bm-PB1-2 during amplification PB1 fragment; Use primer Bm-PA-1 and Bm-PA-2 during amplification PA fragment; Use primer Bm-HA-1 and Bm-HA-2 during amplification HA fragment; Use primer Bm-NP-1 and Bm-NP-2 during amplification NP fragment; Use primer Bm-NA-1 and Bm-NA-2 during amplification NA fragment; Use primer Bm-M-1 and Bm-M-2 during amplification M fragment; Use primer Bm-NS-1 and Bm-NS-2 during amplification NS fragment.Add following reagent successively:
10×PCR buffer 5μL
10mM dNTPs 1μL
Upstream primer (50p moL/L) 1 μ L
Downstream primer (50p moL/L) 1 μ L
Ultrapure water (SW) 31.5 μ L
Instantaneous centrifugal, 94 ℃ of pre-sex change 5min add Expand High Fidelity polysaccharase 0.5 μ L (2.5U) at 75-80 ℃; With 94 ℃ of 40s, 58 ℃ of 35s, 30 circulations of 72 ℃ of 2min; Last 72 ℃ were extended 7 minutes, 4 ℃ of operation 10min.
Get PCR product 5 μ L, the agarose gel electrophoresis with 0.8% is identified.
The clone of PCR product, evaluation and sequencing:
The PCR product is identified through electrophoresis, the whole electrophoresis of remaining product, cutting contains the segmental gel of purpose size, reclaim with Agrose Gel DNA Extraction Kit, be connected with pGEM-Teasy vector, be converted into escherichia coli jm109 competent cell, cut evaluation, PCR product and the product that is connected with the T carrier are served the order-checking of extra large United Gene Science Co., Ltd simultaneously through EcoR I enzyme.
With DNASTAR 4.0 softwares, edit sequence with EditSeq, the Clustal method among the MegAlign becomes the fragment assembly of RT-PCR amplification the complete sequence of each gene.The complete genome sequence login of F strain is at GenBank, accession number is red for Lu AY253750-AY253756[builds, Liu Xiu Buddhist, Shao Weixing, genetic analysis Deng .H9N2 hypotype AIV genome full length sequence mensuration and each gene. the microorganism journal, 2003,43 (4): 434～41.], the HA of D3 strain and NA gene order are seen this paper.
The modification of step 3:D3 strain HA gene and structure D3 strain HA gene transcription/expression plasmid:
Amplify the HA gene and order-checking of D3 strain by the RT-PCR method after, cracking site PQRERRRKKR ↓ the GL of the HA gene of D3 strain is sported cracking site PQIETR ↓ GL (as Fig. 1) of non-virulent influenza virus A/Teal/Hong Kong/W312/97 (H6N1) strain HA according to the sequences Design mutant primer, connect through 3 molecules, the 8 plasmid rescue systems of being cloned into transcribe/expression vector pHW2000 on, form and transcribe/expression plasmid pHW504-HA.
The downstream primer P-MG4-2 of HA gene of being used to suddenly change is positioned at 993-1020nt, with upstream primer Bm-HA-1 pairing, and amplification cDNA 5 ' end fragment HA1 (expect about 1.05kb); Upstream primer P-MG4-1 is positioned at the 1036-1055nt of coding region, with downstream primer Bm-HA-2 pairing, and amplification cDNA 3 ' end fragment HA2 (expect about 0.65kb).Primer is as follows:
Bm-HA-1 5’-TATT
CGTCTCAGGGAGCAAAAGCAGG-3’；
Bm-HA-2 5’-ATAT
CGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3’；
P-MG4-1 5’-ACAT
CGTCTCACTAGAGGATTATTTGGAGCTAT-3’；
P-MG4-2 5’-AGAT
CGTCTCTTCAATTTGAGGGCTTTTTCTGAGTCC-3’；
Primer is synthetic by precious biological (Dalian) company limited.
3 molecules connect the HA cDNA that will modify and are cloned into pHW2000:
3 molecules connect sees Fig. 2, primer pairing amplification HA1 (1.05kb) and two fragments of HA2 (0.65kb) by above-mentioned design, HA1 and HA2 that gel electrophoresis is reclaimed cut, reclaim through the BsmBI enzyme, with equally carry out 3 molecule ligations through transcribing of cutting of BsmBI enzyme/expression vector pHW2000,16 ℃ of effect 12h, be converted into escherichia coli jm109 competent cell, enzyme is cut with PCR and is identified, serves extra large associating genome company sequence verification.
3 molecule ligation systems are as follows:
10 * connection buffer, 1 μ L
T4 dna ligase (3U/ μ L) 1 μ L
HA1 reclaims enzyme and cuts product (0.2 μ g/ μ L) 2.5 μ L
HA2 reclaims enzyme and cuts product (0.2 μ g/ μ L) 4 μ L
PHW2000 reclaims enzyme and cuts product (0.2 μ g/ μ L) 1.5 μ L
Plasmid enzyme restriction is identified: there is the single EcoRI site that does not have on the carrier at the 253bp place of HA cDNA, and there is the single ApaI site that HA inserts not to be had on the fragment at the 645bp place of carrier, and positive plasmid is 1.6kb with EcoRI and ApaI endonuclease bamhi.
Step 4: 6 internal gene and the D3 strain NA gene transcription/expression plasmid that make up the F strain:
Transcribe at 8 plasmids/expression vector pHW2000 in, insert F strain 6 internal gene PB2, PB1, PA, NP respectively, M, NS cDNA form 6 and transcribe/expression plasmid, i.e. pHW201-PB2, pHW202-PB1, pHW203-PA, pHW205-NP, pHW207-M and pHW208-NS; Inserting D3 strain NA gene formation pHW504-NA transcribes/expression plasmid.
The different cloned sequences of each gene are selected correct being used for of sequence to be cloned into 8 plasmids and are transcribed/expression vector pHW2000 through sequential analysis.At first with the BsmBI enzyme cut 6 internal gene of F strain, the NA gene and 8 plasmids of D3 strain are transcribed/expression vector pHW2000, it is as follows that the BsmBI enzyme is cut system (40 μ L), plasmid DNA (0.3 μ g/ μ L) is got 5 μ L.55 ℃ of effect 4h.
10×buffer Y+ 4μL
Goal gene (0.2 μ g/ μ L) 5 μ L
BsmBI(10U/μL) 1μL
SW 30μL
Endonuclease bamhi and carrier are respectively through gel electrophoresis, recovery, connect with the T4 dna ligase again, be converted into escherichia coli jm109 competent cell, choose the bacterium colony enlarged culturing, extract in a small amount plasmid, compare gel electrophoresis with the corresponding plasmid of normal size in 8 pUC pUCs, the positive clone of preliminary evaluation of the same size ,-20 ℃ frozen with-70 ℃.
Step 5: rescue and the evaluation of D3/F-R2/6 strain AIV
The preparation of cell is used in transfection with plasmid and transfection:
With gene fragment from the transformed bacteria of the transcribing of F strain/expression plasmid pHW201-PB2, pHW202-PB1, pHW203-PA, pHW205-NP, pHW207-M, pHW208-NS with from the transformed bacteria enlarged culturing of plasmid pHW504-HA, the pHW506-NA of D3 strain, little upgrading grain test kit upgrading grain with QIAGEN company, and measure content and purity, prepare highly purified plasmid and be used for transfection.Count behind the COS-1 cell dissociation that growth conditions is good, by 10
5The cell concn of individual cells/well places 24 porocyte culture plate overnight incubation.
Virus rescue:
Will be from 6 plasmid pHW201-PB2, pHW202-PB1 of F strain, pHW203-PA, pHW205-NP, pHW207-M, pHW208-NS with from 2 plasmid pHW504-HA, pHW506-NA of D3 strain, by 1: 1 mixed.Make improvements transfection slightly according to Lipofectin Reagent transfection reagent operation instructions: soon blended plasmid and transfection reagent add in the COS-1 cell, put to contain 5%CO
2, in 37 ℃ of incubators, cultivate 24h after, scrape cells transfected and inoculate 10 age in days SPF chicken embryos; The results allantoic fluid continues inoculation 10 age in days SPF chicken embryos after cultivating 48h, observes chicken embryo death and pathology situation every day, collects chick embryo allantoic liquid in good time and carries out the virus evaluation, and the virus of being rescued is called for short the D3/F-R2/6 strain.
Virus is identified:
Blood clotting of D3/F-R2/6 strain (HA) and blood clotting suppress (HI) test to be undertaken by the OIE standard.The plasmid of pHW504-HA, pHW506-NA that contains the plasmid of 6 genes of F strain and D3 strain was in 1: 1 ratio cotransfection COS-1 cell, and the first-generation 10 age in days SPF chick embryo allantoic liquid hemagglutinative titers of inoculation reach 2
8, with the first-generation 10 age in days SPF chick embryo allantoic liquids dilution 10
3～10
5Doubly, after aseptic inoculation 10 age in days SPF chicken embryos went down to posterity, hemagglutinative titer was up to 2
11Make the HI test of D3/F-R2/6 pnca gene reprovision AIV respectively of H1 and H5AIV positive serum, the D3/F-R2/6 strain can be suppressed by the H5 positive serum, and it is 2 that HI tires
9, but can not be suppressed by the H1 positive serum.
Sequence Identification:, identify that by the order-checking of associating gene Shanghai connection polygene research institute method is seen step 2 with HA and the NS gene among the RT-PCR method acquisition D3/F-R2/6 strain AIV.The HA gene of the AIV of D3/F-R2/6 strain as a result is the HA gene of D3 strain, the sequence PQIETR ↓ GL of its cracking site for having suddenlyd change; The NS gene is the NS gene of F strain, and accession number is red for Lu AY253756[builds, Liu Xiu Buddhist, and Shao Weixing waits the genetic analysis of .H9N2 hypotype AIV genome full length sequence mensuration and each gene. microorganism journal, 2003,43 (4): 434～41.].Illustrate that D3/F-R2/6 strain AIV is F strain and D3 strain reprovision virus.
Step 6: the biological characteristics of D3/F-R2/6 strain AIV is measured
The virulence of D3/F-R2/6 strain AIV is measured:
Press the OIE standard, with the aseptic D3/F-R2/6 strain allantoic fluid of 0.2mL dilution in 1: 10, observed 10 days continuously behind the SPF chicken through age 10 6 weeks of intravenous inoculation, do not find the inoculation chicken death, its IVPI is 0, and growing of chicken is normal.
D3/F-R2/6 strain AIV duplicates in that the SPF chicken is intravital:
With tracheae and the cloaca cotton swab sample of the inoculation chicken of gathering in the 3rd, 5,7,9,12 day after the inoculation D3/F-R2/6 strain, inoculate 10 age in days SPF chicken embryos, with isolated viral.Toxin expelling for some time after the inoculation in inoculation chicken tracheae, but promptly separated less than virus in the 9th day; Toxin expelling for some time after the inoculation in inoculation chicken cloaca, but promptly separated in the 12nd day less than virus (table 1).
Table 1 D3/F-R2/6 strain AIV duplicates situation in the chicken body
Table 1 Replication of the D3/F-R2/6 AIV in chickens
| The inoculation back time (my god) | Tracheae virus is separated (%) | Cloaca virus is separated (%) |
| 3 5 7 9 12 | 75 13 13 0 0 | 87 100 100 25 0 |
D3/F-R2/6 strain AIV inoculates 10 age in days SPF chickens 3 week back HI test: recording by the OIE standard that average HI tires is 2
9
The ELD of D3/F-R2/6 strain AIV
50And EID
50Measure: the ELD of D3/F-R2/6 strain AIV
50/ EID
50All be 10
8/ 0.2mL, the mean time to death of chicken embryo is at 80～84h..Dead chicken embryo whole body Mild edema, cephalemia, abdominal surface have blutpunkte, lung's extravasated blood and liver slightly downright bad.
More than test explanation D3/F-R2/6 strain AIV is weak pathogenic H5N1 hypotype AIV.
Pathogenic to the SPF chicken of the stability that D3/F-R2/6 strain AIV goes down to posterity at SPF chicken embryo and the back of going down to posterity:
By the first-generation 10 age in days SPF chick embryo allantoic liquids of transfection COS-1 cell inoculation, the HA hemagglutinative titer reaches 2
8The first-generation 10 age in days SPF chick embryo allantoic liquids were passed for 20 generations continuously, and the HA of dead chick embryo allantoic liquid tires and reaches 2
11(1: 2048) (table 2), the mean time to death 80～84h of chicken embryo.Illustrate that D3/F-R2/6 strain AIV has very high replication in the chicken embryo.
Obtain the HA gene of the 20th generation D3/F-R2/6 strain AIV with the RT-PCR method, by the order-checking of associating gene Shanghai connection polygene research institute, the result prove the HA gene of D3/F-R2/6 strain AIV be the D3 strain causing weak HA gene, its cracking site is PQIETR ↓ GL.D3/F-R2/6 strain AIV is described through going down to posterity, its sequence does not change.To 6 age in week the SPF chicken pathogenic test show that in 10 days that observe, 10 SPF chickens of inoculation do not see death, its IVPI is 0.D3/F-R2/6 strain AIV is described through going down to posterity, its weak pathogenic biological characteristics is very stable.
The HA that table 2 D3/F-R2/6 strain AIV goes down to posterity in SPF chicken embryo tires (2
11)
Table 2 HA titer of D3/F-R2/6 AIV in embronating chicken egg of SPF origin at 5，10，15，20 Passages(2
11)
| Algebraically goes down to posterity | F1 | F5 | F10 | F15 | F20 | |||||
| Extent of dilution | 10 -5 | 10 -6 | 10 -5 | 10 -6 | 10 -5 | 10 -6 | 10 -5 | 10 -6 | 10 -5 | 10 -6 |
| | 2 8 | 2 8 | 2 8 | 2 8 | 2 9 | 2 10 | 2 10 | 2 11 | 2 11 | 2 11 |
Step 7: D3/F-R2/6 strain AIV is to immunoprotection test and the cross immunity protection test of SPF chicken
50 1 age in days SPF chickens are divided into 5 groups, every group 10, during 7 ages in days wherein two groups respectively through each 0.3mL of deactivation oil seepage of neck subcutaneous vaccination D3/F-R2/6 strain AIV deactivation oil seepage, a winding kind D3 strain, one group is made as not vaccination and directly attacks malicious H5N1 hypotype AIV, one group is the normal healthy controls group.Immunity blood sampling in back 21 days separation of serum is surveyed antibody titer, uses 10 respectively
7ELD
50The D3 strain is to the D3/F-R2/6 strain, and D3 strain inactivated vaccine immune group and not vaccination attack directly that the poison group is carried out collunarium, eye drip is attacked poison.Observed 14 days statistics morbidity and death condition continuously.
D3/F-R2/6 strain AIV inactivated vaccine sees Table 3 to immunity and the cross immunity protection test of SPF chicken.The average HI antibody titer 2 that the immunity of D3/F-R2/6 strain AIV deactivation oil seepage is back 21 days
7:0.25, do antigen with the H5N1 hypotype AIV G5 strain of goose source, the average HI antibody titer 2 that records
6.5 ± 0.3The average HI antibody titer 2 that the immunity of D3 strain deactivation oil seepage is back 21 days
5.5 ± 0.2The immune protective rate that D3/F-R2/6 strain AIV and its maternal wild virus D3 strain deactivation oil seepage provide for the SPF chicken all is 100%; H5N1 hypotype AIV attacks poison with the goose source, and its cross immunity protection ratio is 100%.Immune group is all not dead in 7 days after poison is attacked in the D3 strain, and normal healthy controls group chicken is normal.HI antibody titers after the immunity shows D3/F-R2/6 strain AIV inactivated vaccine, and bird flu has the better protection effect to H5N1 hypotype HP.
Table 3 D3/F-R2/6 strain AIV deactivation oil seepage is to immunity and the cross immunity protection efficient of SPF chicken
Table 3 Protective efficacy of D3/F-R2/6 inactivated vaccine in oil emulsion in SPF chickens
| Group | The immunity age in days (my god) | Attack malicious age in days (my god) | Attack toxic agent amount (ELD 50) | Protection efficient (%) | Back 21 days average HI (2 of immunity 11) | ||
| Poison is attacked in the D3 strain | Poison is attacked in the G5 strain | D3 strain antigen | G5 strain antigen | ||||
| D3/F-R2/6 strain vaccine D3/F-R2/6 strain vaccine D3 strain vaccine is attacked the poison contrast | 7 7 7 | 28 28 28 28 | 10 7 10 7 10 7 10 7 | 100 100 0 | 100 | 7±0.25 7±0.25 5.5±0.2 | 6.5±0.3 6.5±0.3 |
Step 8: D3/F-R2/6 strain AIV is to the immunoprotection test and the cross immunity protection test of commercial chicken
Test design is with step 7, and test of the immunoprotection of commercial chicken and cross immunity protection test the results are shown in Table 4.The maternal antibody of commercial chicken is 2
1-3The back 21 days antibody titer of D3/F-R2/6 strain AIV deactivation oil seepage immunity is 2
6.5 ± 0.3, do antigen with the H5N1 hypotype AIVG5 strain of goose source, the average HI antibody titer that records is 2
6 ± 0.2The back 21 days average HI antibody titer of D3 strain deactivation oil seepage immunity is 2
4.2 ± 0.5The immune protective rate of commercial chicken and cross immunity protection ratio all are 100%.Immune group is all not dead in 7 days after D3 strain and G5 strain AIV attack poison, and normal healthy controls group chicken is normal.HI antibody titers after the immunity shows D3/F-R2/6 strain AIV inactivated vaccine, and bird flu has the better protection effect to H5N1 hypotype HP.
Table 4 D3/F-R2/6 strain AIV deactivation oil seepage is renderd a service the immunity and the cross immunity protection of commercial chicken
Table 4 Protective efficacy of D3/F-R2/6 inactivated vaccine in oil emulsion in commercial broiler
chickens
| Group | The immunity age in days (my god) | Attack malicious age in days (my god) | Attack toxic agent amount (ELD 50) | Protection efficient (%) | Back 21 days average HI (2 of immunity 11) | ||
| Poison is attacked in the D3 strain | Poison is attacked in the G5 strain | D3 strain antigen | G5 strain antigen | ||||
| D3/F-R2/6 strain vaccine D3/F-R2/6 strain vaccine D3 strain vaccine is attacked the poison contrast | 7 7 7 | 28 28 28 28 | 10 7 10 7 10 7 10 7 | 100 100 0 | 100 | 6.5±0.3 6.5±0.3 4.2±0.5 2.2±0.15 | 6±0.2 6±0.2 2.2±0.15 2.2±0.15 |
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100409739A CN1313605C (en) | 2005-07-08 | 2005-07-08 | Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100409739A CN1313605C (en) | 2005-07-08 | 2005-07-08 | Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733912A CN1733912A (en) | 2006-02-15 |
| CN1313605C true CN1313605C (en) | 2007-05-02 |
Family
ID=36076529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100409739A Expired - Fee Related CN1313605C (en) | 2005-07-08 | 2005-07-08 | Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1313605C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526718B (en) * | 2010-12-30 | 2013-12-18 | 华中农业大学 | Recombinant H5N1 (Hemagglutinin 5 Neuraminidase 1) avian influenza virus cell vaccine and application thereof |
| CN104164408B (en) * | 2013-05-15 | 2016-12-28 | 普莱柯生物工程股份有限公司 | Anti-newcastle disease, infectious bronchitis and avian influenza vaccine compositions and preparation |
| CN109136199B (en) * | 2018-09-14 | 2020-02-07 | 青岛农业大学 | Replication-defective recombinant H9N2 avian influenza virus expressing H5 subtype HA |
| CN109880835B (en) * | 2019-03-28 | 2022-03-25 | 扬州大学 | Recombinant H9N2 avian influenza virus strain, preparation method thereof, avian influenza vaccine and application thereof |
| CN110468109B (en) * | 2019-07-26 | 2020-12-15 | 军事科学院军事医学研究院军事兽医研究所 | H3N2 subtype canine influenza virus mouse adaptive virulent strain and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1723120A1 (en) * | 1990-05-11 | 1992-03-30 | Институт Микробиологии И Вирусологии Ан Казсср | Strain of influenza virus a (hio ni) for preparing diagnostic preparations |
| CN1618956A (en) * | 2003-11-20 | 2005-05-25 | 中国科学院武汉病毒研究所 | A virus strain for bird flu prevention and its animal infection model |
| CN1635163A (en) * | 2004-11-01 | 2005-07-06 | 中国农业大学 | A method for detecting H5N1 subtype avian influenza virus and its special kit |
-
2005
- 2005-07-08 CN CNB2005100409739A patent/CN1313605C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1723120A1 (en) * | 1990-05-11 | 1992-03-30 | Институт Микробиологии И Вирусологии Ан Казсср | Strain of influenza virus a (hio ni) for preparing diagnostic preparations |
| CN1618956A (en) * | 2003-11-20 | 2005-05-25 | 中国科学院武汉病毒研究所 | A virus strain for bird flu prevention and its animal infection model |
| CN1635163A (en) * | 2004-11-01 | 2005-07-06 | 中国农业大学 | A method for detecting H5N1 subtype avian influenza virus and its special kit |
Non-Patent Citations (3)
| Title |
|---|
| H5亚型禽流感重组鸡痘病毒活载体疫苗的免疫效力 贾立军 张如宽 刘秀梵，扬州大学学报(农业与生命科学版)，第24卷第2期 2003 * |
| H5亚型禽流感重组鸡痘病毒活载体疫苗的免疫效力 贾立军 张如宽 刘秀梵，扬州大学学报(农业与生命科学版)，第24卷第2期 2003;广州地区禽H9N2亚型流感病毒的发现及感染人调查 李钏华 周秀珍 李美霞，中华实验和临床病毒学杂志，第18卷第3期 2004 * |
| 广州地区禽H9N2亚型流感病毒的发现及感染人调查 李钏华 周秀珍 李美霞，中华实验和临床病毒学杂志，第18卷第3期 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1733912A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1678345A (en) | Multi plasmid system for the production of influenza virus | |
| CN1533434A (en) | influenza vaccine composition | |
| CN113913394B (en) | Artificial recombinant H5N6 influenza virus and preparation method and application thereof | |
| CN1065912C (en) | Genetically engineered attenuated viruses | |
| CN113913395B (en) | Artificial recombinant H5N8 influenza virus, and preparation method and application thereof | |
| WO2016134678A1 (en) | New influenza a virus mammalian cell adapted strain and preparation and use thereof | |
| CN113853215A (en) | High growth influenza virus | |
| CN1869234A (en) | Recombination newcastle disease LaSota weak virus vaccine for expressing poultry influenza virus H5 sub type HA protein | |
| Liu et al. | Genetic conservation of hemagglutinin gene of H9 influenza virus in chicken population in Mainland China | |
| CN1313605C (en) | Gene recombinant fowl influenza virus D3/F-R2/6 and its construction method | |
| Yuan et al. | Surveillance and molecular characterization of Newcastle disease virus in seafowl from coastal areas of China in 2011 | |
| Ibrahim et al. | A single dose of inactivated oil-emulsion bivalent H5N8/H5N1 vaccine protects chickens against the lethal challenge of both highly pathogenic avian influenza viruses | |
| CN103118704B (en) | Modified viral strains, and method for improving the production of vaccine seeds of influenza virus | |
| CN110168079A (en) | Novel pig cell line for virus production | |
| CN102526718B (en) | Recombinant H5N1 (Hemagglutinin 5 Neuraminidase 1) avian influenza virus cell vaccine and application thereof | |
| CN1754959A (en) | Preparation process and application of genetic engineering subunit vaccine of infectious bursal disease | |
| CN1827775A (en) | Nucleotide sequence for detecting newcastle disease virus, kit and detection method thereof | |
| TW201249996A (en) | Novel vaccines against pandemic influenza virus A/H1N1 | |
| CN1644686A (en) | High yielded strain of mammalia influenza virus, its recommbined strains and preparation and use thereof | |
| CN1451038A (en) | Attenuated influenza virus useful as vaccine | |
| CN1780916A (en) | Chicken RNA polymerase I promoter and use thereof | |
| CN1522760A (en) | Bivalent gene engineering vaccine of fowl infectious bursal disease and pasteurellosis | |
| CN1303212C (en) | Non-structural protein gene NS1 of avian influenza virus and its preparation method and use | |
| CN1884498A (en) | Recombinant fowl influenza virus strain, its preparation method and the vaccine obtained therefrom | |
| CN1807609A (en) | Thermostable lactase preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070502 Termination date: 20160708 |